Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neuroendocrine Tumors 15Paraganglioma 4Meningioma 4Carcinoma, Neuroendocrine 4Pheochromocytoma 3Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Medullary 2Carcinoid Tumor 2Somatostatinoma 1Serotonin Syndrome 1Prostatic Neoplasms 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Neuroblastoma 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Disease Progression 1Carcinoma, Merkel Cell 1Carcinoid Heart Disease 1Breast Neoplasms 1Advanced Lung Neuroendocrine Tumor 1Adenoma, Islet Cell 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × lutetium Lu 177 dotatate × Clear all
NCT04529044 2026-06-05

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
10 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡